Cost of oral antibiotic therapy

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 302-307

  Nightingale, Charles H ^a   Quintiliani, Richard ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LORACARBEF; OFLOXACIN; PENICILLIN V;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INTERACTIONS; HUMANS;

EID: 0030978144     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Nightingale CH, Belliveau PP, Quintiliani R. Cost issues and considerations when choosing antimicrobial agents. Infect Dis Clin Pract 1994;3:8-11.
2. Atkinson HC, Chambers ST, McGinlay AM. Antibiotic therapy costs. N Z Med J 1989;102:409-11.
3. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1989;324:384-94.
4. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991;66:1249-59.
5. Molavi A. Cephalosporins: rationale for clinical use. Am Fam Physician 1991;43:937-48.
6. Fassbender M, Lode H, Schaberg T, Borner K, Koeppe P. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993;16:646-53.
7. Goldman MP, Longworth DL. The role of azithromycin and clarithromycin in clinical practice. Cleve Clin J Med 1993;60:359-64.
8. Adam D. Clinical use of the new macrolides, azalides, and streptogramins in pediatrics. J Chemother 1992;4:371-5.
9. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 1989;27:194-203.
10. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-19.
11. Anonymous. Red book update. Montvale, NJ: Medical Economics, 1996.
12. Anonymous. Physicians' desk reference, 50th ed. Montvale, NJ: Medical Economics, 1996.
13. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(suppl 3A):5S-11.
14. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370-4.
15. Gladen HE. Computer modeling antibiotic therapy costs. Impact of therapeutic range. Drugs 1988;35(suppl 3):208-13.
16. Klepser ME, Nightingale CH, Quintiliani R. Pharmacoeconomic analysis of piperacillin/tazobactam versus ticarcillin/clavulanate for the treatment of intra-abdominal infections. Pharm Ther 1994;19(suppl 7):24-32.
17. Feldman JA, DeTullio PL. Medication noncompliance: an issue to consider in the drug selection process. Hosp Formul 1994;29:204-11.
18. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990;2:19-33.
19. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
20. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J 1987;295:814-18.
21. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med 1963;268:1334-8.
22. Katz BP, Zwickl BW, Caine VA, Jones RB. Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 1992;19:351-4.
23. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
24. Davey P, Parker S. Cost effectiveness of once-daily oral antimicrobial therapy. J Clin Pharmacol 1992;32:706-10.
25. U.S. Department of Labor, Bureau of Labor Statistics. Month Labor Rev 1992.
26. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(suppl 3A):40S-5.
27. Therasse DG. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections. Am J Med 1992;92(suppl 6A):S20-6.
28. Periti P, Novelli A, Schildwachter G, Schmidt-Gayk H, Ryo Y, Zuck P. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother 1990;26(suppl E):63-9.
29. Stutman HR, Arguedas AG. Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media. Clin Infect Dis 1992;14(suppl 2):S204-8.
30. Pelletier LL Jr. Review of the experience with cefprozil for the treatment of lower respiratory tract infections. Clin Infect Dis 1992;14(suppl 2):S238-43.
31. Hamilton RA, Gordon T. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992;26:1507-11.
32. Wijnands WJA, Vree TB, Van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986;22:677-83.
33. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23: 106-31.
34. Gentry LO. Therapy with newer oral, β-lactam and quinolone agents for infections of the skin and skin structures: a review. Clin Infect Dis 1992;14:285-97.
35. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
36. Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis 1994;18:951-7.
37. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
38. Pichichero ME. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med 1995;25:390-403.